Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC A DARST

Allopathic & Osteopathic Physicians Dermatology

NPI
1144208158
CMS profile
188291
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,867.10

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,788.15 137
Education $78.95 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC A DARST

NPI 1144208158 · CMS profile ID 188291

Allopathic & Osteopathic Physicians / Dermatology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144208158?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC A DARST, NPI 1144208158, CMS profile ID 188291. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144208158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MARC A DARST, NPI 1144208158, CMS profile ID 188291. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144208158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MARC A DARST, NPI 1144208158, CMS profile ID 188291, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1144208158?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $2,867.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $15.4108/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996849237 CMS
Dermavant Sciences, Inc. $55.3508/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991175131 CMS
Amgen Inc. $23.9508/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020629149 CMS
Almirall LLC $17.5708/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038197587 CMS
GENZYME CORPORATION $7.9308/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707813 CMS
GENZYME CORPORATION $39.7508/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707819 CMS
AbbVie Inc. $16.7808/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589553 CMS
AbbVie Inc. $9.8908/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589549 CMS
LEO Pharma Inc. $0.3608/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464501 CMS
LEO Pharma Inc. $1.0108/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464505 CMS
LEO Pharma Inc. $7.3708/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464509 CMS
AbbVie Inc. $27.1608/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589545 CMS
AbbVie Inc. $7.0707/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589541 CMS
MAYNE PHARMA COMMERCIAL LLC $8.0807/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060817579 CMS
Dermavant Sciences, Inc. $26.4907/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991175127 CMS
Dermavant Sciences, Inc. $22.1007/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991175123 CMS
E.R. Squibb & Sons, L.L.C. $22.5607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015514915 CMS
AbbVie Inc. $8.2707/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589537 CMS
Almirall LLC $18.2407/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038197431 CMS
LEO Pharma Inc. $18.9407/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464497 CMS
Amgen Inc. $29.7207/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020629147 CMS
Galderma Laboratories, L.P. $15.7007/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059690011 CMS
AbbVie Inc. $6.0907/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589533 CMS
Janssen Biotech, Inc. $12.5906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988246571 CMS
Dermavant Sciences, Inc. $4.5006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991175119 CMS
MAYNE PHARMA COMMERCIAL LLC $4.8006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060817569 CMS
Novartis Pharmaceuticals Corporation $27.4506/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991790193 CMS
PFIZER INC. $31.7306/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049536955 CMS
LEO Pharma Inc. $22.6906/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464493 CMS
Almirall LLC $20.7706/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038197415 CMS
Almirall LLC $2.4906/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038197419 CMS
Lilly USA, LLC $12.4106/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031885367 CMS
PFIZER INC. $18.6106/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050543797 CMS
GENZYME CORPORATION $8.4506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707771 CMS
AbbVie Inc. $18.1906/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589529 CMS
MAYNE PHARMA COMMERCIAL LLC $7.9405/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060817565 CMS
LEO Pharma Inc. $6.3205/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464485 CMS
LEO Pharma Inc. $1.2705/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053464489 CMS
Dermavant Sciences, Inc. $5.5805/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991175115 CMS
Janssen Biotech, Inc. $22.5305/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988246585 CMS
Amgen Inc. $28.0905/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020629151 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $20.2005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051617961 CMS
AbbVie Inc. $25.6005/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589525 CMS
AbbVie Inc. $7.2805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589521 CMS
Dermavant Sciences, Inc. $18.3505/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991175111 CMS
GENZYME CORPORATION $10.8505/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707727 CMS
AbbVie Inc. $5.9705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996589517 CMS
Almirall LLC $24.4605/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038197463 CMS
E.R. Squibb & Sons, L.L.C. $15.9005/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015514839 CMS
Sun Pharmaceutical Industries Inc. $22.8805/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053913461 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,413.20 119
PY2020 $1,405.44 74
PY2021 $2,053.96 82
PY2022 $2,425.49 117
PY2023 $2,867.10 139
PY2024 $4,665.46 131
PY2025 $2,317.47 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $213,548.69 58
PY2024 Principal investigator $212,673.47 53
PY2023 Recipient $199.16 1
PY2023 Principal investigator $140,737.15 46
PY2022 Principal investigator $95,217.05 25
PY2021 Principal investigator $24,887.47 20
PY2020 Principal investigator $48,876.00 31
PY2019 Principal investigator $73,941.77 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202532801
Principal investigator 1 PFIZER INC. $2,119.78 12/31/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228747338
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.00 12/29/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431574
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $490.00 12/29/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431576
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $426.25 12/29/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431578
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $532.50 12/29/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431580
Principal investigator 1 PFIZER INC. $1,015.95 12/17/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228748309
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,061.63 12/12/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431572
Principal investigator 1 ABBVIE INC. $1,716.90 12/04/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202527406
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,998.19 12/04/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431568
Principal investigator 1 PFIZER INC. $3,350.10 11/26/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228728275
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $21,000.00 11/24/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797010
Principal investigator 1 PFIZER INC. $2,304.25 11/05/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228737467
Principal investigator 1 PFIZER INC. $1,015.95 10/22/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228754282
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,335.81 10/10/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431564
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 10/08/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431558
Principal investigator 1 PFIZER INC. $1,015.95 09/26/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228768718
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,335.81 09/25/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431540
Principal investigator 1 PFIZER INC. $6,546.00 09/12/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228753514
Principal investigator 1 ABBVIE INC. $3,139.80 09/03/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202507583
Principal investigator 1 PFIZER INC. $1,243.45 08/23/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228767391
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,610.00 08/20/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431536
Principal investigator 1 PFIZER INC. $8,639.81 07/29/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772382
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $350.00 07/28/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431528
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $350.00 07/28/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431530
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $425.00 07/28/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431532
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,061.63 07/18/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431526
Principal investigator 1 PFIZER INC. $6,293.57 07/17/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228762990
Principal investigator 1 PFIZER INC. $2,031.90 07/02/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228787078
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,724.00 06/18/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431522
Principal investigator 1 ABBVIE INC. $1,702.05 06/03/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202488889
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,061.63 05/27/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431518
Principal investigator 1 PFIZER INC. $888.55 05/16/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772274
Principal investigator 1 ABBVIE INC. $1,491.00 05/12/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202484629
Principal investigator 1 ABBVIE INC. $1,100.00 05/12/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202484641
Principal investigator 1 ABBVIE INC. $726.00 05/06/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202481523
Principal investigator 1 PFIZER INC. $1,090.05 05/06/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228765723
Principal investigator 1 PFIZER INC. $1,243.45 05/03/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228776737
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,899.63 04/15/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431512
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,061.63 03/24/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431510
Principal investigator 1 PFIZER INC. $6,293.57 03/22/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781828
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,465.00 03/21/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431506
Principal investigator 1 ABBVIE INC. $3,931.65 03/07/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202461479
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,123.25 03/03/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431502
Principal investigator 1 PFIZER INC. $7,354.58 02/11/2025 Non-covered Recipient Entity
DJL Clinical Research PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228757476
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,246.50 02/07/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431496
Principal investigator 1 ABBVIE INC. $193.85 02/06/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447589
Principal investigator 1 ABBVIE INC. $329.40 02/06/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447592
Principal investigator 1 ABBVIE INC. $183.60 02/06/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447596
Principal investigator 1 ABBVIE INC. $68.85 02/06/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447600
Principal investigator 1 Eli Lilly and Company $79,158.48 02/05/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187880847
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $800.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431482
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $400.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431484
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $50.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431486
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $150.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431488
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $50.00 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431490
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $468.75 01/17/2025 Non-covered Recipient Entity
DJL Clinical Research, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431492
Principal investigator 1 ABBVIE INC. $3,367.95 01/02/2025 Non-covered Recipient Entity
DJL CLINICAL RESEARCH PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202434144